A Study of Napabucasin in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase III Randomized, Open-Label Clinical Study of Napabucasin (GB201) in
Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic
Pancreatic Cancer Following Front-Line Chemotherapy Failure
Phase:
Phase 3
Details
Lead Sponsor:
1Globe Biomedical Co., Ltd. 1Globe Health Institute LLC